Results 81 to 90 of about 11,328,563 (174)

The Impact of Anti-Amyloid Immunotherapies on Stroke Care

Anti-amyloid immunotherapies have recently emerged as treatments for Alzheimer’s disease. While these therapies have demonstrated efficacy in clearing amyloid-β and slowing cognitive decline, they have also been associated with amyloid-related
Mariel G. Kozberg, Philippe A. Bilodeau, John R. Dickson   +2 more
core   +1 more source

Amyloid related imaging abnormalities (ARIA)

, 2021
Frank Gaillard, Rohit Sharma, Niklas Froemmel   +2 more
openaire   +1 more source

Table1_Imaging spectrum of amyloid-related imaging abnormalities associated with aducanumab immunotherapy.docx

Alzheimer's Disease (AD) is a leading cause of morbidity. Management of AD has traditionally been aimed at symptom relief rather than disease modification.
Manoj Tanwar (17737653), C. Austin Wheeler (17737647), Parnian Shobeiri (9117877), Marissa Natelson Love (17737650), Ramin Shahidi (16805001), Zahra Saadatpour (17737644), Mohammadreza Alizadeh (17737641), Houman Sotoudeh (14786503)   +7 more
core   +1 more source

Efficacy and safety of gantenerumab in the treatment of Alzheimer's disease: A meta-analysis of randomized controlled trials

Archives of Gerontology and Geriatrics Plus
Introduction: Gantenerumab has garnered considerable attention for its potential to modify the natural course of Alzheimer's disease. However, recent studies have shown mixed results for the use of this medication for the treatment of Alzheimer's Disease.
Milene Vitória Sampaio Sobral, Victor Gonçalves Soares, Ocilio Ribeiro Gonçalves, Victoria Städler de Abreu, Lucas Cael Azevedo Ramos Bendaham, Brenda Leticia Lopes Batista, M.D., Marco Antonnio Rocha dos Santos, M.D., MsC   +6 more
doaj   +1 more source

Amyloid‐Related Imaging Abnormalities, ARIAs: Experience of a Single Center in the Context of Clinical Trials with Anti‐Amyloid Antibodies

Alzheimer's & Dementia
Abstract Background Amyloid‐related imaging abnormalities (ARIAs) are complications associated with anti‐amyloid therapy in Alzheimer’s disease (AD). ARIAs include ARIA‐edema (ARIA‐E) and ARIA‐hemorrhage (ARIA‐H), which may present asymptomatically or with mild symptoms.
Villar, Ainhoa Atorrasagasti, Villino‐Rodríguez, Rafael Angel, Espinoza‐Vinces, Christian, Pérez‐Prol, Cristina, Jimenez‐Huete, Adolfo, Dominguez, Pablo, Riverol, Mario   +6 more
openaire   +2 more sources

Three major effects of APOEε4 on Aβ immunotherapy induced ARIA

Frontiers in Aging Neuroscience
The targeting of amyloid-beta (Aβ) plaques therapeutically as one of the primary causes of Alzheimer’s disease (AD) dementia has been an ongoing effort spanning decades.
Kate E. Foley, Kate E. Foley, Donna M. Wilcock, Donna M. Wilcock   +3 more
doaj   +1 more source

New Discoveries in Amyloid‐Related Imaging Abnormalities with Hemorrhage (ARIA‐H) and Anti‐Amyloid Beta Monoclonal Antibodies

Alzheimer's & Dementia
Abstract Background Amyloid‐related Imaging Abnormalities(ARIA) are adverse effects that occur during amyloid beta monoclonal antibody treatment for Alzheimer's disease, including edema‐type ARIA and hemorrhage‐type ARIA(ARIA‐H).
An, Dinghao, Zou, Xinxin, Xu, Yun
openaire   +2 more sources

Amyloid-related imaging abnormalities in patients with Alzheimer\u27s disease treated with bapineuzumab: A retrospective analysis

, 2012
Background: Amyloid-related imaging abnormalities (ARIA) have been reported in patients with Alzheimer\u27s disease treated with bapineuzumab, a humanised monoclonal antibody against amyloid β.
Tampieri, Donatella, Black, Ronald, Porsteinsson, Anton P., Sperling, Reisa, Brashear, H. Robert, Raskind, Murray, Kinney, Gene G., Fox, Nick C., Brooks, David J., Lu, Yuan, Barakos, Jerome, Salloway, Stephen, Grundman, Michael, Morris, Kristen A., Sabbagh, Marwan, Gregg, Keith M., Honig, Lawrence S., Lieberburg, Ivan, Liu, Enchi, Arrighi, H. Michael   +19 more
core   +1 more source

Clonal expansion of cytotoxic CD8⁺ T cells in lecanemab-associated ARIA

Nature Communications
Amyloid-related imaging abnormalities (ARIA) are the principal safety concern limiting anti-amyloid therapies for Alzheimer’s disease, yet their biology remains unclear.
Lance A. Johnson, Kai Saito, Akhil V. Pallerla, Jessica L. Funnell, Ashley R. Ezzo, Chelsea M. Song, Douglas A. Harrison, Noah J. Norton, Lauren C. Moore, Linda J. Van Eldik, David W. Fardo, Greg E. Cooper, Josh M. Morganti   +12 more
doaj   +1 more source

Emergency Care for Patients on Amyloid-Targeting Therapies in Alzheimer\u27s Disease [PDF]

The introduction of novel amyloid-targeting therapies for Alzheimer’s disease presents challenges for emergency clinicians. Patients on these therapies may present with amyloid related imaging abnormalities (ARIA) that are only detectable on magnetic ...
Chiang, Gloria, Sutherland, Jennifer, Melady, Don, Hagerman, Thomas K, Suh, Michelle, Biese, Kevin, Devi, Gayatri, Kennedy, Maura   +7 more
core   +1 more source